NeuroQuest: Advancing Alzheimer's Disease Detection using Deep Learning Algorithms

CSE 498: Capstone Project

Sheikh Rafia Noor Maisha (19202103037)
Sihab Mahmud (19202103032)
Sourov Karmokar (19202103020)
Md. Monzurul Alam Sajal (19202103007)
Sourov Hazra (19202103036)

Submitted in partial fulfillment of the requirements of the degree of Bachelor of Science in Computer Science and Engineering

Under the kind guidance of

Md. Mamun Hossain
Assistant Professor
Dept. of CSE

Bangladesh University of Business and Technology (BUBT)

January, 2024

Abstract

Alzheimer's disease which is a neurological disorder casts a shadow over cognition, robbing individuals of control over their thoughts, memory, and linguistic abilities. Its impact extends beyond cognitive functions; patients often grapple with a loss of autonomy, as the ability to navigate daily life becomes increasingly elusive. The economic toll, measured at a staggering USD 305 billion USD, underscores the human cost and the financial burden it places on healthcare systems and societies at large. Advanced deep learning models are added to conventional diagnostic techniques to improve Alzheimer disease classification accuracy. Driven by the challenge of complex medical data and limited access, this research aspires to revolutionize Alzheimer's disease detection. By integrating diverse methods, it seeks to achieve high accuracy and build a complete classification system, empowering medical practitioners with a potent tool for accurate diagnosis. Prioritizing patient privacy, transparency, and ethical principles, this study harnesses the power of deep learning algorithms to explore new avenues in renal disease. Our goal: enhancing early detection, improving treatment outcomes, lowering healthcare costs, and expanding access to care. While challenges remain, this research paves the way for a more effective and equitable approach to Alzheimer disease management.

Index Terms: Alzheimer's disease, Deep learning, Classification accuracy, Medical data, Patient privacy, Treatment outcomes.

Declaration

This is hereby declared that the work titled **"NeuroQuest: Advancing Alzheimer's Disease Detection using Deep Learning Algorithms"**, is the outcome of a project carried out by me under the supervision of Md. Mamun Hossain, in the Department of Computer Science and Engineering, Bangladesh University of Business and Technology, Dhaka 1216. It is also declared that this Capstone Project or any part of it has not been submitted elsewhere for the award of any degree or diploma. It contains no materials previously published or written by any other person except where due reference is made in the project.

Signature of Authors

Maisha

Sheikh Rafia Noor Maisha

ID: 19202103037

Sihab

Sihab Mahmud

ID: 19202103032

Sourov

Sourov Karmokar

ID: 19202103020

Sajal

Md.Monzurul Alam Sajal

ID: 19202103007

Sourav

Sourov Hazra

ID: 19202103036

Certification

This is to certify that Sheikh Rafia Noor Maisha , Sihab Mahmud, Sourov Karmokar, Md. Monzurul Alam Sajal, Sourov Hazra students of B.Sc. in CSE have completed their capstone project work titled 'NeuroQuest : Advancing Alzheimer's Disease Detection using Deep Learning Algorithms' satisfactorily in partial fulfillment for the requirement of B.Sc.in CSE, Bangladesh University of Business and Technology in the year 2024.

Project Supervisor

Md. Mamun Hossain

Assistant Professor

Department of Computer Science and Engineering (CSE)

Bangladesh University of Business and Technology (BUBT)

Dedication

Dedicated to our parents for all their love and inspiration...

Acknowledgement

We are thankful and expressing our gratefulness to Almighty Allah who offers us His divine blessing, patient, mental and physical strength to complete this project work. We are deeply indebted to our project supervisor Md. Mamun Hossain, Assistant Professor, Department of Computer Science and Engineering (CSE), Bangladesh University of Business and Technology (BUBT). His scholarly guidance, important suggestions, work for going through our drafts and correcting them, and generating courage from the beginning to the end of the research work has made the completion of this project possible. We would like to express our deep gratitude to our Teacher Md. Mamun Hossain, Assistant Professor, Department of Computer Science and Engineering (CSE), Bangladesh University of Business and Technology (BUBT). It was fantastic to get help from him and without his support it will be tough for us to reach the accurate goal. A very special gratitude goes out to all our friends for their support and help in implementing our works. The discussions with them on various topics of our works have been very helpful for us to enrich our knowledge and conception regarding the work. Last but not the least; we are highly grateful to our parents and family members for supporting us spiritually throughout writing this report and our life in general.

Approval

The Project titled 'NeuroQuest : Advancing Alzheimer's Disease Detection using Deep Learning Algorithms' and submitted by Sheikh Rafia Noor Maisha, Sihab Mahmud, Sourov Karmokar, Md. Monzurul Alam Sajal, Sourov Hazra, ID NO: 19202103037, 19202103032, 19202103020 and 19202103007,19202103036 Department of Computer Science and Engineering, Bangladesh University of Business and Technology (BUBT), has been accepted as satisfactory in partial fulfillment of requirements for the degree of Bachelor of Science in Computer Science and Engineering and approved as to its style and contents.

Supervisor
Md. Mamun Hossain
Assistant Professor
Department of Computer Science and Engineering (CSE)
Bangladesh University of Business and Technology (BUBT)

Chairman
Md. Saifur Rahman
Assistant Professor
Department of Computer Science and Engineering (CSE)
Bangladesh University of Business and Technology (BUBT)

Copyright

1. Sheikh Rafia Noor Maisha (19202103037)
2. Sihab Mahmud (19202103032)
3. Sourov Karmokar (19202103020)
4. Md. Monzurul Alam Sajal (19202103007)
5. Sourov Hazra (19202103036)

List of Figures

List of Figures

List of Table

List of Contents

Contents

Chapter - 01

1 Introduction

1.1 Introduction

Alzheimer disease(AD) is a kind of neurological disorder which destroys brain tissues and patience lose control thought ability, memory loss, and language problem as also many people diagnosed with the condition will die from another cause. Alzheimer's disease affects over 35 million people worldwide and its global healthcare cost is 305 billion USD[3]. It is a costly and chronic disease. Traditional and Computerised tests: mild AD (n = 26); questionable dementia (QD; n = 43); major depression (n = 37) and healthy controls (n = 39) which given by memory, attention and executive function[19]. Cardiovascular and carotid artery disease which are two major risk factors for AD, can plot or independently induce chronic brain hypoperfusion (CBH) decades before any symptoms of cognitive impairment are expressed[4]. A difference between a normal person and Alzeimar diseases affected person is shown in Figure[1] 1.



Figure 1: Normal Brain and Alzheimer's Brain

Figure 1 visually encapsulates the stark contrast between a normal brain and one ravaged by Alzheimer's disease. This visual representation serves as a poignant reminder

[1] $https://www.researchgate.net/figure/Neuroanatomical-comparison-of-normal-brain-and-Alzheimer-s-disease-brain-A-B-Normal_{fig}4_300271729$

of the urgency to develop advanced detection methods capable of identifying subtle signs and initiating timely interventions. In this pursuit, NeuroQuest emerges as a pioneering force, leveraging advanced deep learning algorithms to propel Alzheimer's disease detection into a new era.

Using deep learning algorithms detection of Alzheimer's disease detects multi-class of AD and classification of using MRI data that can detect early detect of AD and predict as also shows many graph which give correct accuracy of AD. These advanced deep learning models detect AD using the medical dataset with some train and test datasets. Traditional and computerized tests serve as diagnostic tools, attempting to categorize individuals into subgroups based on the severity of the disease and its impact on memory, attention, and executive function.The clinical challenges posed by Alzheimer's disease are compounded by the intricate interplay of contributing factors.

NeuroQuest positions itself as a vanguard in this endeavor, harnessing the power of deep learning algorithms to detect and classify Alzheimer's disease using MRI datasets. This technological leap holds the promise of early detection, a critical factor in altering the trajectory of the disease and improving patient outcomes. As we delve into the realm of NeuroQuest, the application of advanced deep learning algorithms becomes a beacon of hope. Beyond its diagnostic prowess, NeuroQuest contributes to the broader landscape of medical research, providing precise accuracy metrics that enhance our understanding of Alzheimer's disease. As we navigate the intricate nuances of this neurological challenge, NeuroQuest stands as a testament to the power of deep learning algorithms in reshaping our approach to Alzheimer's disease diagnosis and, by extension, the lives of those affected by this relentless adversary.

The adoption of NeuroQuest, with its focus on advancing Alzheimer's Disease Detection through the integration of MRI scans and cutting-edge deep learning algorithms such as Convolutional Neural Networks (CNNs) and InceptionV3, is driven by a multitude of compelling reasons. The intricate details captured by MRI scans enable a comprehensive examination of brain structures, offering a nuanced understanding of the subtle abnormalities associated with this complex neurodegenerative disorder. The deep learning algorithms embedded within NeuroQuest, particularly CNNs and InceptionV3, play a pivotal role in enhancing sensitivity and specificity in Alzheimer's disease detection. Their ability to discern intricate patterns within the complex datasets derived from MRI scans ensures a high level of accuracy, instilling confidence in healthcare professionals and patients alike. This heightened accuracy is especially crucial in the early detection and intervention stages of Alzheimer's disease, where timely recognition of subtle markers can pave the way for more effective treatment strategies. The application of NeuroQuest extends beyond clinical diagnoses;The collaboration between advanced deep learning algorithms and MRI datasets provides a wealth of insights, fostering a deeper comprehension of the disease and propelling the field towards innovative treatment approaches. The integration of NeuroQuest with advanced deep learning technologies represents more than just a diagnostic tool; it embodies a commitment to precision, early intervention, and technological innovation. In essence, NeuroQuest, with its emphasis on MRI integration and sophisticated deep learning algorithms, emerges not only as a diagnostic solution but as a beacon of progress in the ongoing quest to understand, detect, and ultimately mitigate the impact of Alzheimer's disease.

1.2 Existing Model

We use a deep learning model using CNN to detect early detection of Alzheimer's disease and what stage it is in using brain MRI data set. The main purpose of our project is to see if a person above 50 has Alzheimer's disease or what stages it is. The models we use try to improve the accuracy of the results to accurately diagnose the disease. We use CNN, InceptionV3 models of deep learning in our project to achieve exact accuracy. We chose a large set of MRI data as input. Since our data set is based on a large image dataset, we perform pre-processing of the images in various ways. First, we pre-train the MRI data with the models. Using our project when a person is diagnosed with Alzheimer's disease or knows what stage of the disease they are in, they have the opportunity to tell their family what is going on in their life because AD can lead to memory loss, speech impairment, and even death in many people.

1.3 Problem Statement

Alzheimer's Disease Detection We classify the disease through deep learning models. Since it is related to the neurology medical field, the result must be accurate and sensitive. The MRI data we use needs to be well filtered because if the images are blurry then the model cannot be trained and in that case, it come out low or inaccurate accuracy of detection. Alzheimer's disease is a progressive neurodegenerative disorder that severely impacts cognitive function and memory, leading to significant challenges for affected individuals and their families. Alzheimer's disease detection is a complex task that needs more advanced and precise diagnostic tools that can reliably identify early signs. So we aim to make a substantial impact in the field of Alzheimer's disease research and patient care.

1.4 Motivation

Many over 50s in our society are suffering from Alzheimer's disease or in a mild stage but they don't know they have Alzheimer's disease. By advancing the detection and diagnosis of Alzheimer's disease using deep learning algorithms, our project aims to make a substantive impact on healthcare outcomes. After being implemented with a correct accuracy result this project helps to improve patient care and quality of life. This project's significance of early detection in enabling healthcare professionals to provide potentially slow down the progression of the disease and improve patient outcomes. The use of deep learning algorithms and methodologies, the report contributes to the growing body of knowledge in the field of deep learning and its strong impact on healthcare. This research can inspire and guide future studies and investigations in the neurology healthcare field. It allows the broader healthcare professionals, It allows the broader scientific community, healthcare professionals, neurological researchers, and the public to gain insights into the advancements and potential of deep learning algorithms in Alzheimer's disease detection.

1.5 Objectives of the Project

The objectives of our research work are as follows:

- Develop a deep learning model specifically congenial for Alzheimer's disease classification.
- Improve the accuracy and sensitivity of AD detection compared to traditional diagnostic methods.
- Detection of early Alzheimer's disease provides healthcare professionals and neurologists with reliable tools for identifying this AD in the early stage, mild stages and as soon as possible gives that patient's treatment plans and interventions.
- Deep learning model using MRI datasets to ensure its reliability, accuracy, and generalizability.
- Provide a foundation for future studies and advancements in the field.
- Researchers, neurologists, and data scientists are essential objectives of the project.
- Provide awareness about the advancements in AD detection and the potential impact on early diagnosis, treatment, and care.

1.6 Contribution

The overall contribution of the research work is:

- The project that we have identified from the research paper has some limitations in deep learning and we have highlighted the changes in the future.
- Our neuroQuest's deep learning model provides healthcare professionals with a tool for patient care and treatment planning.
- Deep learning algorithms are used to analyze large amounts of medical MRI data.
- We have implemented models such as CNN, InceptionV3 for accurate outcomes.
- Identifying patterns and MRI, the model offers insights into the structural and functional changes in the brain associated with the disease.

1.7 Significance of the Research

The exploration of Alzheimer's Disease classification using NeuroQuest and deep learning algorithms holds paramount significance across multiple dimensions, marking a transformative journey in healthcare innovation.

- **Advancement in Medical Diagnostics:** NeuroQuest's application in Alzheimer's disease detection represents a pioneering approach in medical diagnostics. The integration of advanced deep learning algorithms facilitates automated and highly accurate classification of neurological conditions through the analysis of various data sources, including imaging. The precision achieved has the potential to redefine early detection and intervention strategies, improving patient outcomes while minimizing the need for invasive procedures.

- **Integration of Vision and Linguistic Comprehension:** The utilization of these models bridges the gap between visual data, such as brain imaging, and clinical descriptions. This fusion enriches the medical decision-making process, providing a comprehensive understanding of Alzheimer's disease manifestations.

- **Enhanced Efficiency in Time and Resources:** The automated image classification expedites the process, allowing healthcare practitioners to allocate more time to personalized patient care and strategic treatment planning.

- **Potential for Telemedicine Advancements:** This technology empowers specialists to remotely assess diagnostic images and offer expert insights to healthcare providers, particularly in underserved or remote regions.

- **Educational and Research Impact:** This research becomes a cornerstone resource for educators, researchers, and students, fostering a deeper understanding of the transformative potential of advanced technologies in neurology.

- **Customized CNN and InceptionV3:** The development of customized CNN and InceptionV3 with hidden layers and connected layer provides a noble approach to modeling for Alzheimer classification.

- **Ethical Considerations and Societal Impact:** NeuroQuest's comprehensive approach to addressing ethical concerns associated with medical data privacy, security, and informed consent exemplifies the commitment to responsible and socially impactful applications of deep learning in Alzheimer's disease detection. Ethical considerations are embedded in the core of NeuroQuest's implementation, ensuring a patient-centric and privacy-preserving approach.

In conclusion, the significance of this research extends beyond technological advancements. NeuroQuest, in advancing Alzheimer's Disease Detection, becomes a beacon for transformative changes in healthcare practices, education, and ethical considerations. Its potential for widespread societal impact positions NeuroQuest not just as a tool but as a catalyst shaping the future landscape of Alzheimer's disease diagnosis through deep learning algorithms.

1.8 Organization of Report

This capstone work is organized as follows. chapter 1 highlights the background and Chapter 2 literature review on the field of neurology healthcare which detects advancing Alzheimer's disease using Deep Learning Algorithms. Chapter 3 contains the proposed architecture and details the overall system in the future. Chapter 4 contains Result analysis.

1.9 Conclusion

In conclusion, Advancing AD Detection using Deep Learning represents a significant contribution to the field of healthcare and specifically to the diagnosis and management of Alzheimer's disease. The main aim of using deep learning algorithms gives correct accuracy, sensitivity, and early detection. NeuroQuest's deep learning model analyzes medical MRI data brain imaging scans, genetic markers, and clinical records, to identify patterns associated with the disease. The project's contributions to healthcare research and public awareness have the potential to make a lasting impact on the lives of individuals affected by this neurodegenerative disorder.

Chapter - 02

2 Background Study

2.1 Introduction

In this chapter basically we have discussed studies completed by previous authors from other authors such as project neurodegenerative disorder Alzheimer's disease detection using deep learning algorithms.

2.2 Literature Review

Mehedi et al.[18] in their system ADNI MRI imaging scans are categorized as NC, MCI, EMCI, LMCI, SMC, and AD. A CNN model is utilized for detection, which requires JPEG format for image data. Hence, the 3D DICOM images are converted to 2D JPEG images using a DICOM converter application. To detect AD using MRI data, five pre-trained deep learning models (VGG16, MobileNetV2, AlexNet, ResNet50, and InceptionV3) are explored to identify the most effective transfer learning strategy for classification.

In this study enhanced Alorf et al.[1] the multi-label classification of Alzheimer's disease stages compared to previous limited studies. They accomplished this by extracting the functional connectivity networks of the brain using rs-fMRI data and employing deep learning techniques. Their results demonstrate an average classification accuracy of 77.13% and a multi-label classification accuracy of 84.03%.

Chyr et al.[3]developed a novel deep-learning method called DOTA for repurposing effective FDA-approved drugs to treat Alzheimer's Disease. In their study, they predicted that antipsychotic drugs with circadian effects, such as quetiapine, aripiprazole, and risperidone, target crucial brain receptors involved in memory, learning, and cognition. These receptors include serotonin 5-HT2A, dopamine D2, and orexin receptors. Consequently, the implementation of DOTA has shown improvements in patient cognition, circadian rhythms, and the pathogenesis of Alzheimer's Disease.

This paper proposed Islam et al.[10] a deep convolutional neural network (CNN) approach that utilizes brain MRI data analysis to identify different stages of Alzheimer's disease. Unlike most existing approaches that focus on binary classification, their model achieves superior performance for multi-class classification, leading to a significant improvement in early-stage diagnosis of AD. This research presents a promising direction for the development of advanced diagnostic tools for AD, with potential implications for early intervention and improved patient care.

Khachaturian et al. analyze vast biological and clinical data [13] to find patterns and correlations that could identify targets and create innovative compounds. Their study shows the potential of this approach in accelerating drug discovery and predicting drug effectiveness and safety for neurodegenerative disorders.

Used MRI data Luo et al.[14] of 47 Alzheimer's disease (AD) patients and 34 normal controls (NC) from ADNI1. A convolution neural network (CNN) was employed for AD recognition, with 66% of the data used for training and 33% for testing. During testing, seven middle cross-sections were extracted as patches, and if all seven patches were classified as NC, the data was considered as normal control.

The 3D images[21]normalized to Talairach coordinates and brain-masked. Weighted t-tests were conducted at the 95% confidence interval. The eigenvalues of the selected most important eigenbrain were used as input features for SVM classification, enabling the development of a CAD system to detect Alzheimer's disease and normal control groups with reported performance and POL-KSVM method achieved a competitive accuracy of 92.36%.

Used a subset Feng et al.[6] of 469 subjects with 3127 MRI samples from the ADNI dataset. They compared information, recognition tests, and biomarker levels in three groups (AD, MCI, NC). CNN, a deep learning method, extracted features from MRI images using convolutional, pooling, fully connected layers, and a classifier.

Ghazal et al.[9] proposed ADDTLA system model utilizes MRI scans for early disease detection and classification using deep learning techniques, with the inclusion of transfer learning through the implementation of a pre-trained AlexNet convolutional network model and the model achieves a 91.7% accuracy.

Proposed the MultiAZ-Net ensemble model Ismail et al.[11] that combines MRI and PET neuroimaging techniques for early diagnosis of Alzheimer's disease, utilizing InceptionV3, AlexNet, and ResNet-18 models. The Multi-Objective Grasshopper Optimization Algorithm enhances the classification performance by training these models with multi-modal data, resulting in more informative and discriminative features.SVM, achieved an average accuracy of 92.3% with a standard deviation of 5.5% in the classification results.

Nazem et al.[16] proposed various nano-diagnostic methods, such as DNA-nanoparticle conjugates, nanoparticle surface plasmon resonance, scanning tunneling microscopy, and two-photon Rayleigh spectroscopy, were employed by the authors. They also examined nano treatment approaches, such as neuroprotective agents and nanocarriers designed for precise drug delivery. In conclusion, the authors highlighted the potential of nanotechnology to enhance early detection and treatment of Alzheimer's disease (AD).

Folego et al. [7]employed a 3D CNN for feature extraction from MRI scans, resulting in a classifier with an accuracy of 85.4%.

Weiner et all. [20] conducted a review of papers published by the ADNI to assess the progress that has been made in the study of AD. He found that ADNI has made significant progress and that the papers he reviewed provide valuable information about the early stages of AD and the biomarkers and treatments that are being developed for the disease. The ADNI has made significant progress in the study of AD. Neuroimaging can be used to diagnose AD with high accuracy. New biomarkers for AD are being developed.

Birkenbihl et all. [2]used a variety of methods to evaluate the AD data landscape. They conducted a literature review, analyzed data from existing databases, and conducted interviews with experts in the field. The teammate found that the AD data landscape is fragmented and heterogeneous. There is a lack of standardized data collection and sharing practices, which makes it difficult to integrate data from different sources. They also found that the quality of AD data is variable. Some data sets are of high quality, while others are of low quality. This makes it difficult to draw reliable conclusions from AD research.

Pluta et all. [17] used a variety of methods to investigate the blood cells. They looked at the expression of different genes, the levels of different proteins, and the morphology of the cells. The found that there were some differences in the blood cells of AD patients and healthy controls. For example, the platelets of AD patients had higher levels of the protein CD63.However, the authors also found that the differences between the blood cells of AD patients and healthy controls were not very large. This suggests that blood cells may not be the best biomarkers for AD.

Frisoni et al. [8] scanned 29 patients with mild AD and 26 healthy controls using MRI. They then used VBM to measure the volume of grey matter in different regions of the brain in both groups. The authors found that the patients with mild AD had significantly less grey matter in the hippocampus, amygdala, and other regions of the brain than the healthy controls. This suggests that VBM can be used to detect grey matter loss in mild AD. The authors concluded that VBM is a promising technique for detecting grey matter loss in mild AD. They noted that further research is needed to confirm this.

This paper proposes a deep learning model called DEMNET that uses convolutional neural networks and long short-term memory networks to classify dementia stages from MR images Murugan et al [15] . The paper reports a high accuracy of 95.23% on a separate testing dataset when using the SMOTE technique to balance the classes. However, the paper lacks a clear explanation of the model architecture, the data preprocessing steps, the hyperparameter values, and the evaluation metrics. It also does not compare the model with other existing methods or baselines.

Jo et. al. [12] propose two deep learning methodologies for Alzheimer's Disease (AD) diagnosis and classification based on neuroimaging data. These methodologies include Stacked Autoencoders (SAE) and Convolutional Neural Networks (CNN). The paper reports high accuracies of 94.4% for AD/CN classification and 80.6% for MCI to AD conversion prediction using multimodal neuroimaging data. The paper also shows that the combination of different types of neuroimaging scans improves the performance compared to using a single modality. However, the paper lacks a clear explanation of the SAE and CNN architectures, the data preprocessing steps, the hyperparameter values, and the evaluation metrics.

In This paper present, a machine-learning approach Diogo et al. [5] for early Alzheimer's disease diagnosis using structural MRI scans and multiple diagnostic labels. The method achieves high accuracies of 93.8% for AD/CN classification, 86.7% for MCI/CN classification, and 80.0% for MCI/AD classification on two public databases. However, the paper lacks details on data preprocessing, hyperparameter values, and evaluation metrics, and it does not compare the proposed approach with existing diagnostic tools or assess its impact on patient outcomes.

The paper proposes a new self-attention mechanism and a structural distilling model for Alzheimer's disease diagnosis by Zhu et al. [22]. The self-attention mechanism learns the global dependencies among different brain regions, and the structural distilling model transfers knowledge from a teacher network to a student network. However, the paper lacks a clear explanation of the self-attention mechanism and the structural distilling model, including their mathematical formulations, architectures, and parameters. Additionally, it does not provide any visualizations or interpretations of the learned features or attention maps. Despite these shortcomings, the paper reports high accuracies of 98.8% for AD/CN classification, 95.6% for MCI/CN classification, and 92.4% for MCI/AD classification using data from the ADNI database.

2.3 Problem Analysis

Table 1: Previous research works in terms of objectives, used models, and possible research gaps

Reference	Research Purpose	Used Methods	Focused Contribution	Challenges/ Research Gaps
Alorf et al. [1]	Automatic Alzheimer's Disease Recognition from MRI Data Using Deep Learning Method	Five pre-trained deep learning models (VGG16, MobileNetV2, AlexNet, ResNet50, and InceptionV3)	VGG16, MobileNetV2, AlexNet, ResNet50 and InceptionV3 models are 78.85%, 86.85%, 78.86%, 80.48%, and 82.32% respectively	Didn't use hybrid model which could be implemented on ADNI fMRI PET datasets
Wei Feng et al.[6]	Automated MRI-Based Deep Learning Model for Detection of Alzheimer's Disease Process	CNN,deep learning method, extracted features from MRI images using convolutional, pooling, fully connected layers, and a classifier.	Classification using 2D-CNN, 3D-CNN, and 3D-CNN-SVM was observed to be 82.57% ± 7.35%, 89.76% ± 8.67%, and 95.74% ± 2.31%, respectively	Did not take into account the follow-up MRIs and did not include a comparison of diagnoses made by radiologists.
Ghazal et al.[9]	Alzheimer Disease Detection Empowered with Transfer Learning	ADDTLA system model utilizes MRI scans, classification using deep learning techniques, transfer learning a pre-trained AlexNet convolutional network model.	The model achieves a 91.7% accuracy	Accuracy is not so good.
Folego et al.[7]	Alzheimer's disease detection through whole-brain 3D-CNN MR	3D CNN for feature extraction from MRI scans	Develop new biomarkers for AD, track the progression of the disease and to develop new treatments.	Should development of novel treatments for the disease.
Alorf et al.[1]	Multi-label classification of Alzheimer's disease stages from resting-state fMRI-based correlation connectivity data and deep learning.	Improve classification from previous limited studies extracting the brain's functional connectivity networks from rs-fMRI data and employing two deep learning approaches.	The Model achieves average 77.13% accuracy, 84.03% for multi-label classification.	Need a larger and more diverse dataset.

Table 1 Continue

Reference	**Research Purpose**	**Used Methods**	**Focused Contribution**	**Challenges/ Research Gaps**
Jyoti et al.[10]	Brain MRI analysis for Alzheimer's disease diagnosis using an ensemble system of deep convolutional neural networks.	A deep convolutional neural network using brain MRI data analysis. While most of the existing approaches perform binary classification.	Proposed an ensemble system of deep convolutional neural networks for Alzheimer's disease diagnosis.	Evaluate the ensemble system on a larger dataset
Frisoni et al.[8]	Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry.	statistical parametric mapping (SPM99) algorithms	statistical parametric mapping	Only detect (voxel-based morphometry) to detect presence and severity of regional grey matter density but not used any model for detect stages accurately.
Diogo et al.[5]	Early diagnosis of Alzheimer's disease using machine learning: a multi-diagnostic, generalizable approach	Linear discriminant analysis, support vector machine, random forest, and k-nearest neighbors.	Use machine learning models for decision making	They do not evaluate the impact of the classifiers on patient outcomes, such as quality of life, cognitive function, or disease progression.
Ours	NeuroQuest: Advancing Alzheimer's Disease Detection using Deep Learning Algorithms	Use Deep learning classify models	Detect Alzheimer's disease stage and early detect	Need more research

2.4 Conclusion

Deep learning algorithms are used to automatically analyze neuroimaging data to address the limitations of current AD diagnostic methods. Overcoming challenges related to data availability, interpretability, generalization, ethics, and integration into clinical workflow is crucial for its successful implementation. When using deep learning models yield accurate result, it can revolutionize AD diagnosis, leading to earlier interventions and improved management of this debilitating disease.

Chapter - 03

3 Proposed System

3.1 Introduction

In this chapter we have introduced leverage deep learning algorithms to advance the detection and diagnosis of Alzheimer's disease (AD). Also discussed are some method ideas that happen when we are implemented.



Figure 2: Steps of work

We have shown this in shown in Figure 2 a work process that how we started from data collection and last Data Pre-processing also classify the AD stages. Early and accurate diagnosis which plays a crucial role in managing the disease and improving patient outcomes. Diagnostic methods rely on clinical assessments and neuroimaging techniques like MRI scans. However, these methods can be subjective and time-consuming. Deep learning techniques, particularly convolutional neural networks (CNNs) and transfer learning using models like Inception, offer promising avenues for automated and objective AD classification.

3.2 Feasibility Analysis

A feasibility study is an important stage in determining the feasibility and viability of adopting a solution or approach. A feasibility study evaluates the possible viability of building and implementing a classification system in the context of Alzheimer classification using Deep learning and Transfer learning. The main points of the feasibility analysis for Alzheimer classification are:

1. Technical Feasibility: This aspect evaluates whether the required technol-ogy and resources are available to develop the Alzheimer disease classification. It involves assessing the availability of suitable hardware, software frameworks, and programming expertise to implement and maintain the system.

2. Data Availability: The availability of a sufficiently large and diversified collection of Alzheimer's MRI pictures is crucial. The feasibility analysis determines whether or not a dataset correctly representing different forms of Alzheimer MRI is available. Furthermore, the dataset's quality and accuracy are assessed, since the classification model's success is strongly dependent on the quality of the training data.

3. Algorithm Suitability and Performance: Assess the computational complexity of the CNN and transfer learning with Inception, considering factors such as the number of layers, parameters, and computational operations required for training and inference.

4. Model Development and Validation: This model deals with overfitting, underfitting as large level of class imbalance ..

5. Hardware and Infrastructure: Identify any hardware limitations in terms of processing power, memory, storage, and compatibility with deep learning frameworks and explore the viability of cloud-based solutions or specialized hardware (e.g., GPUs, TPUs) if on-premises resources are insufficient. Consider the scalability of the infrastructure for potential future growth or increased usage.

6. System Integration and Deployment: Evaluate the compatibility of the deep learning models with current clinical systems and data pipelines, addressing challenges in data transfer, model deployment, and results interpretation. Identify necessary workflow adjustments to incorporate model outputs effectively into clinical decision-making processes.

7. Ethical and Regulatory Compliance: Ensure compliance with data privacy regulations and implement robust data security measures. Assess the potential for biases in the models and implement mitigation strategies to promote fairness and equity. Determine the required regulatory approvals for clinical use and plan for the necessary validation and documentation processes.

8. Cost Considerations: Estimate costs for data acquisition, preprocessing, algorithm development, hardware, software, and cloud services. Consider costs for model deployment, maintenance, updates, and ongoing computational resources. Evaluate the potential cost savings or clinical benefits that could offset the investment in the long term.

3.3 Requirement Analysis

1. System Functionality Requirements: One of the fundamental aspects of NeuroQuest's functionality is the incorporation of advanced deep learning algorithms. These algorithms are meticulously crafted to analyze complex patterns in medical images related to Alzheimer's disease.Classifly Alzheimer of MRI image.

2. User Interaction and Accessibility: The interface is designed to simplify tasks for healthcare professionals, facilitating easy uploading and processing of medical data. A well-designed graphical interface enhances the overall user experience, allowing professionals to navigate through the system seamlessly. These visualizations are essential for healthcare professionals to interpret and understand diagnostic outcomes effectively, aiding in clinical decision-making.

3. Data Management and Accessibility: The system ensures secure access to a diverse and comprehensive dataset of Alzheimer's disease-related medical images. This dataset is not just extensive but also carefully curated to encompass various demographics and disease stages. Such diversity enhances NeuroQuest's ability to recognize patterns across different scenarios, contributing to its diagnostic accuracy.

4.Data standardization: NeuroQuest's approach to managing medical images. Processes are implemented to standardize image sizes, formats, and metadata. Access to a large collection of MRI alzheimer data for test and train. Additionally, NeuroQuest defines meticulous steps for preparing training data, optimizing the efficiency of its deep learning algorithms.

5. System Performance: Criteria The performance criteria of NeuroQuest are foundational to its effectiveness in Alzheimer's disease classification. These criteria encompass various aspects aimed at ensuring the system's accuracy, efficiency, and scalability. One of the key components is the specification of accuracy metrics for the classification and detection of Alzheimer's disease.

Optimizing image processing time is another critical aspect of NeuroQuest's performance criteria. Timeliness is crucial in medical diagnoses, and NeuroQuest prioritizes the reduction of image processing time to provide prompt and efficient results.

Scalability is also a significant consideration for NeuroQuest.Our system is engineered to handle a substantial volume of medical images concurrently. This scalability ensures that NeuroQuest remains efficient and effective, even as the dataset grows, accommodating the evolving demands of healthcare practices.

6. Security and Patient Privacy Measures: Ensuring the security and privacy of patient data is a non-negotiable aspect of NeuroQuest's design. The system implements robust measures to safeguard sensitive medical information and adhere strictly to data protection laws and regulations. One of the primary measures is the implementation of data encryption for the secure transit and storage of sensitive medical information.This commitment is integral to upholding patient privacy rights and maintaining the trust of both healthcare professionals and patients. By implementing stringent security measures, NeuroQuest aims to create a secure and reliable environment for Alzheimer's disease classification.

7. Technical Infrastructure Requirements: The technical infrastructure of NeuroQuest is foundational to its seamless operation. This includes specifying compatible operating systems and browsers to ensure seamless integration with diverse technology environments commonly used in healthcare settings. In addition to compatibility, NeuroQuest defines minimum hardware requirements to ensure the smooth functioning of the system. These requirements encompass specifications for processing power, memory, and storage, guaranteeing that the system can handle the computational demands associated with processing and analyzing medical images.

8. Compliance with Regulations and Ethics: Compliance with regulations and ethical standards is a cornerstone of NeuroQuest's development. The system is designed to ensure strict compliance with relevant medical device regulations governing Alzheimer's disease detection. This includes adherence to standards set by regulatory bodies to guarantee the system's reliability and safety in clinical use. Upholding the highest standards of patient data confidentiality is another critical aspect of NeuroQuest's ethical framework. The system obtains all necessary consents and implements stringent measures to ensure the secure handling of sensitive medical information. By prioritizing compliance with regulations and ethical considerations, NeuroQuest aims to build trust among healthcare professionals and patients, establishing itself as a reliable and ethical solution for Alzheimer's disease detection.

9. User-Focused Design Principles, Maintenance, Support, and Training: The system's intuitive user interface and navigation are designed to optimize user experience. The design prioritizes simplicity without compromising the depth of functionality, catering to the diverse needs of healthcare professionals. Clear error messages and user instructions are integrated into the system to assist healthcare professionals in navigating various features, contributing to a seamless user experience.User technical support is a priority, with a dedicated support system in place to address any issues promptly, minimizing downtime and ensuring a seamless user experience. Comprehensive training materials and documents are developed to facilitate efficient system use. Training sessions are conducted to ensure the successful utilization of NeuroQuest in Alzheimer's disease detection, tailored to the specific needs and expertise levels of the users.

10. Ongoing System Maintenance and Support: Ensuring the continuous and reliable operation of NeuroQuest requires a well-defined strategy for ongoing system maintenance and user support. These aspects are critical to sustaining the system's effectiveness and ensuring its seamless integration into the dynamic landscape of healthcare practices.This commitment to continuous improvement ensures that NeuroQuest remains secure, up-to-date, and aligned with the latest advancements in both technology and Alzheimer's disease research.

11. Training and Documentation Guidelines: NeuroQuest places a strong emphasis on the development of comprehensive training materials. These materials cover a spectrum of topics, ranging from basic system navigation to advanced diagnostic capabilities. The goal is to provide healthcare professionals with the resources they need to navigate NeuroQuest confidently and extract meaningful insights from the diagnostic results. Conducting training sessions is a proactive approach taken by NeuroQuest to ensure the successful utilization of the system. By investing in comprehensive training and documentation, NeuroQuest aims to facilitate a smooth onboarding process and ongoing utilization of the system, ultimately enhancing the proficiency of healthcare professionals in Alzheimer's disease detection.

In conclusion, the holistic approach to ongoing system maintenance, user support, and training/documentation underscores NeuroQuest's commitment to the long-term success of its implementation. By addressing these aspects, NeuroQuest aims to create an environment where healthcare professionals feel supported, empowered, and confident in utilizing the system to its full potential. This meticulous approach contributes to the overall effectiveness of NeuroQuest in advancing Alzheimer's disease classification using deep learning algorithms.

3.4 Methodology: proposed Architecture



Figure 3: Methodology

The overall benefit of this methodology is that it allows to train deep learning models to make accurate predictions on Alzheimer'sMRI data, even if we don't have a lot of labeled training data. This is because transfer learning allows to take a pre-trained model that has been trained on a large dataset of labeled data. The specific steps involved in the methodology of our Alzheimer disease classification:

1. Data Pre-processing: This step involves cleaning and preparing our data for training. This include tasks such as removing noise, converting data to a format that the model can understand, and scaling the data. Resize the dataset 128x128.

2. Data Splitting: This step involves dividing our data into training, validation, and test sets. The training set is used to train the model, the validation set is used to tune the hyperparameters of the model, and the test set is used to evaluate the final performance of the model.

3. Model selection: There are deep learning models to choose from, and the best model for our task will depend on several factors, such as the size and type of our data, and the desired accuracy of our predictions.

4. Model training: This step involves training the model on the training data. The model learn from the train data and develops a set of rules that it can use to make predictions on new data.

5. Model validation: This step involves using the validation set to evaluate the performance of the model. The model will be evaluated on a number of metrics, such as accuracy, precision, and recall.

6. Transfer learning: This step involves taking a pre-trained model and fine-tuning it on our own data. This can be a very effective way to improve the performance of a model, especially if you don't have a lot of labeled data.

7. Model testing: This step involves using the test set to evaluate the final performance of the model. The model will be evaluated on a number of metrics, such as accuracy, precision, and recall.

3.5 Alzheimer MRI data-set

3.5.1 Data-Set Collection: Alzheimer MRI data

Data Collection: Description and Sources:
The Kaggle dataset selected for our project encompasses MRI images categorized into four classes for both training and testing sets: Mild Demented, Moderate Demented, Non-Demented, and Very Mild Demented. This dataset includes one folder which containing original images. Notably, the original images are available for use in validation or testing.The data in Kaggle's Alzheimer's Dataset - 4 Class of Images-
https://www.kaggle.com/datasets/tourist55/alzheimers-dataset-4-class-of-images
holds significant importance for our project.Our goal is to encourage the incorporation of augmented images alongside their original counterparts in Alzheimer's disease classification tasks.The dataset is licensed under the GNU Lesser General Public License 3.0, fostering an ethos of open collaboration and sharing within the scientific community. With an information usability rating of 8.75, this dataset is well-regarded for its applicability in various domains, including image classification, computer vision, deep learning, and medicine. While the dataset is not expected to receive frequent updates, it stands as a valuable resource for researchers and practitioners working on advancements in Alzheimer's disease detection.

3.5.2 Data Preprocessing

Data Preprocessing for Alzheimer's Disease Classification:

Initiate the data preprocessing phase by addressing and refining the Alzheimer's disease dataset. This crucial step involves converting batching, resizing or shuffling.

In Figure 4 total data shown that there are four classes and each class total data size. In image pre-processing step images are organized into batches of 32, improving model training efficiency. Images are resized to 128x128 pixels for consistency and computational efficiency. Images are randomly shuffled to enhance model generalization and prevent biases during training. Setting a seed (42) ensures reproducibility of shuffling across different runs.



Figure 4: Dataset Volume

3.5.3 Data Splitting:

The total MRI image is 5134 so we split it into train,test, validation for our further work:

- Train data: Contains 80% of the data, used for training the model.
- Talidation data: Contains 10% of the data, used for validation during training.
- Text data: Contains the remaining 10% of the data, used for final performance evaluation.

3.5.4 Data Weighting:

Data weighting for Alzheimer's Disease Classification: Class weights are a technique used in machine learning to address class imbalance. They assign higher weights to the minority class, allowing the model to give more importance to its samples during training and reduce bias towards the majority class.As our four class but they have a large level of imbalance so we are using class weighting. In our multiclass classification :

- Extracting Class Labels: Extract the target labels (y train) from the training data (train data), assuming each data point is a tuple where the second element is the label.

- Calculating Class Weights: It specifies a 'balanced' weighting scheme, which aims to balance the contribution of different classes during model training, especially when classes are imbalanced. It provides the unique classes (np.unique(y train)) and the labels (y train.numpy()) to compute the weights.

- Creating a Dictionary of Class Weights: Here commonly used in machine learning to address class imbalance issues during training. By assigning higher weights to underrepresented classes, it ensures that the model gives more attention to these classes, potentially improving its performance on those classes.

3.5.5 Model Selection

In image-based applications, a convolutional neural During the model selection process for Alzheimer's disease classification, we investigate a range of Deep learning architectures. In Our dataset, which includes MRI Alzheimer pictures which are used to train including Convolutional Neural Networks, other image-based classification models as InceptionV3. Their performance is evaluated using criteria such as accuracy, precision, recall, and F1-score. We find the model with the greatest accuracy and best generalization capabilities for classsify alzheimer disease by comparing and analyzing the results. To prevent overfitting, we employ techniques such as droup out and normalization during the training phase. The resulting model is then poised for deployment, armed with the capability to make informed classifications on new, unseen MRI images related to Alzheimer's disease.

3.5.6 Model Training and Validation

In the critical phase of model development, we initiate the training process using the preprocessed Alzheimer's disease dataset. Regularization techniques are employed to prevent overfitting, ensuring the model's capacity to generalize to unseen instances. Validation plays a pivotal role during training, where a portion of the dataset distinct from the training set is reserved. This validation set enables continuous monitoring of the model's performance. Iterative training-validation cycles refine the model's parameters, optimizing its ability to accurately classify different stages of Alzheimer's disease.Metrics such as accuracy, precision, recall, and F1 score are meticulously assessed on the validation set, providing insights into the model's effectiveness.The culmination of this phase sets the stage for model deployment and further evaluation against real-world instances.

3.5.7 Result Visualization

In this phase, we employ result visualization techniques to provide a clear and insightful representation of our Alzheimer's disease classification model's performance.

- We generate visualizations that illustrate key metrics such as accuracy, precision, recall, and F1 score, providing a comprehensive overview of the model's classification performance across different disease stages.

- Confusion matrices may be visualized to showcase the model's ability to correctly classify instances and identify potential areas of misclassification.

- Accuracy offers a broad picture of how effectively a model performs throughout every category. However, it may not be the optimal statistic to use when confronting unbalanced data-sets in which one class is far more common than the others. A high accuracy may be deceiving in such instances if the model is primarily predicting the majority of the class.

- Additionally, we visualize the feature importance or activation maps to highlight the regions of MRI images that significantly contribute to the model's decision-making process. Interpretability is crucial in the medical field, and visualizations aid in conveying the model's decision rationale to healthcare professionals and researchers.

3.6 Summary of the chapter:

In this chapter, we present a comprehensive overview of innovative approaches geared towards advancing the detection of Alzheimer's disease through the utilization of deep learning algorithms. Beginning with the integration of advanced deep neural networks, our approach seeks to leverage the capabilities of these models for improved feature extraction and pattern recognition. Furthermore, the adoption of multi-modal fusion techniques is explored, emphasizing the amalgamation of diverse data sources such as imaging, genetic markers, and clinical data to create a more holistic understanding of the disease. Transfer learning strategies are introduced as a means to overcome data limitations, allowing models to generalize effectively in the context of Alzheimer's disease detection. In addition, our modes prioritize the incorporation of explainability and interpretability features to enhance the transparency of model decisions, fostering trust within the medical community. Real-time monitoring solutions form a crucial aspect of our proposal, enabling continuous data analysis for prompt intervention and personalized treatment strategies.In essence, our proposed modes collectively constitute a multifaceted and ethically sound approach to revolutionize Alzheimer's disease detection and monitoring.

Chapter - 04

4 Implementation and Performance Evaluation

4.1 Introduction

The convolution technique plays a crucial role in deep learning and image classification. Utilizing deep learning methods, we can effectively classify images related to Alzheimer's disease and distinguish individuals who may or may not have the condition. Early detection and treatment are paramount for any disease, particularly Alzheimer's.

4.2 Dataset Details

Our datasets (MRI) contain bundles of information about diseases Alzheimer's Disease (AD). The dataset includes four distinct classes of image data, each corresponding to different stages of the disease. The classes are as follows:

1. Very Mild Demented
2. Non Demented
3. Moderate Demented
4. Mild Demented

The total number of images in the dataset is 5134, providing a diverse and extensive collection of data for analysis and model training. This variety allows for a thorough examination of Alzheimer's Disease across different stages, contributing to the robustness and depth of our research and findings.



Figure 5: Data-set sample

4.3 Flow of Work

Convolutional Neural Networks are being used more and more in MRI image processing, particularly the classification of Alzheimer. CNNs are used in this scenario to evaluate medical images such as MRIs in order to identify and categorize various Alzheimer disease.

Input Shape-128x128x3 represents the dimensions of the MRI scan images (height, width, color channels) and In hidden layer(Convolutional Layers- filter(32,64,128),kernal size =3x3,Maxpooling2d-3x3)),Dense fully connected layers-(filter-(128,64)) so overall our cnn model is custom model designed by us.



Figure 6: CNN

InceptionV3, a powerful convolutional neural network architecture, has been employed for the classification of Alzheimer's Disease (AD) using our dataset. It is a member of



Figure 7: InceptionV3

Google's Inception family of convolutional neural networks (CNNs). Inception v3 is especially well-suited to jobs requiring visual data, which makes it potentially suitable to the identification and alzheimer classification using medical imaging.

4.4 Summery

In the Implementation and Performance Evaluation phase, we seamlessly integrated both the InceptionV3 and CNN models for Alzheimer's Disease classification, utilizing an 80-10-10 split for training, testing, and validation on our diverse four-class MRI dataset. Through rigorous implementation, these models demonstrated robust feature extraction, resulting in high accuracy, precision, and recall rates. This dual-model approach not only affirms their collective efficacy but also positions them as promising diagnostic tools for Alzheimer's Disease. InceptionV3, and traditional convolutional neural networks (CNN) in tandem for nuanced medical image analysis, contributing to a deeper understanding of AD progression.

4.5 Results and Discussion:

Having meticulously trained and optimized our deep learning algorithms on various modalities of data related to Alzheimer's Disease (AD), we now turn our attention to the crucial stage of evaluating their actual performance. In this section, we delve into the results obtained on independent test datasets, scrutinizing the accuracy, sensitivity, specificity, and other relevant metrics for each algorithm. We conduct comprehensive comparisons between different models and modalities, exploring strengths and limitations.

MODEL	TRAIN ACCURAY
Cnn	98.98
InceptionV3	89.94

Table 2: Train model accuracy

In this Table 2 shows that the CNN model train accuracy is 98% and InceptinV3 89.94% . So the CNN model is higher than InceptionV3 model.

The confusion matrix (fig8) shows the performance of a deep learning algorithm that



Figure 8: Confusion Matrix

has been trained to detect Alzheimer's disease. The rows represent the actual diagnoses, and the columns represent the predicted diagnoses. The numbers in the cells represent the number of patients who were actually in each category and were predicted to be in each category.

In the fig9 shows the training and validation accuracy curve which is performed based on CNN model where last epoch accuracy 98.98 and validation accuracy 98.83.



Figure 9: Model Accuracy

The Training loss and Validation loss curve are shown on fig10, which are generated based on the CNN model.



Figure 10: Model Loss

Fig11 shows the results of a CNN test on MRI scans of the brain from test data.

```
[ ] model.evaluate(test_data)

16/16 [==============================] - 36s 1s/step - loss: 0.0419 - accuracy: 0.9883
[0.04192796349525452, 0.98828125]
```

Figure 11: CNN Test Accuracy

Fig12 shows the results of a InceptionV3 test on MRI scans of the brain from test data.

```
[ ] inception_model.evaluate(test_data)

16/16 [==============================] - 14s 60ms/step - loss: 0.4268 - accuracy: 0.8457
[0.42677411437034607, 0.845703125]
```

Figure 12: InceptionV3 Test Accuracy

	Precision	Recall	F1-score	Support
MildDemented	1.00	0.99	0.99	67
ModerateDemented	1.00	1.00	1.00	3
NonDemented	1.00	0.99	0.99	264
VeryMildDemented	0.98	1.00	0.99	178

Table 3: CNN Percision, Recall, F1-score Analysis

The table 3 shows that the model is very good at classifying cells as either "MildDemented" or "NonDemented", with both precision and recall scores of 1.00. This means that the model correctly classified all of the cells that were actually MildDemented or NonDemented. The model is also good at classifying cells as "VeryMildDemented", with a precision score of 0.98 and a recall score of 1.00. The F1-score is a harmonic mean of the precision and recall scores. It takes into account both the precision and recall of the model. The F1-score for all of the dementia classifications is 0.99, which is very good.The support column shows the number of cells in each category.

	Precision	Recall	F1-score	Support
MildDemented	0.74	0.91	0.82	69
ModerateDemented	0.50	1.00	0.67	2
NonDemented	0.91	0.88	0.90	264
VeryMildDemented	0.85	0.81	0.83	177

Table 4: InceptionV3 Percision, Recall, F1-score Analysis

In Table 4,Precision is the ratio of correctly classified examples to the total number of examples the model predicted as belonging to a certain class.Recall is the ratio of correctly classified examples to the total number of examples that actually belong to a certain class.F1-score is a harmonic mean of precision and recall, and it is a measure of a model's accuracy on a certain class.The table shows that the CNN performed well on classifying non-demented patients, with a precision of 0.91, recall of 0.88, and F1-score of 0.90. The model also performed well on classifying mildly demented patients, with a precision of 0.74, recall of 0.91, and F1-score of 0.82.

Fig13 shows the results of a CNN test on MRI scans of the brain. So in this visualizes a 5x5 grid of images from a test dataset, along with their actual and predicted labels. It highlights correct predictions with green titles and a ”Right” text, and incorrect predictions with a maroon title and ”Wrong” text, providing a visual overview of the CNN model’s performance.



Figure 13: CNN Test Result Analysis

Fig14 shows a visual the results of an InceptionV3 test on MRI scans of the brain.



Figure 14: InceptionV3 Test Result Analysis

4.6 Summery of the chapter

In the result analysis section, the chapter succinctly summarizes the application of Convolutional Neural Networks (CNN) and Insertion V3 in Alzheimer's disease detection. It evaluates the accuracy of both models, comparing their performance metrics to discern their effectiveness in enhancing early diagnosis and underscoring the potential for improved neuroimaging data analysis.

Chapter - 05

5 Standrads, Constraints and Milestone

5.1 Standards

5.1.1 Data Standardization:

A pivotal emphasis on robust data standardization standards. These encompass uniform formatting, normalization procedures, and meticulous feature engineering guidelines to ensure consistency and comparability across diverse alzheimer MRI dataset. The organization prioritizes metadata documentation, quality control checks, and cross-dataset compatibility, fostering transparency and reliability in their research. Scalability measures, regular audits, and a data governance framework further solidify Neuro Quest's dedication to data quality and reliability. Open data principles and a commitment to continuous improvement reflect a collaborative and adaptive approach, while the organization remains poised to embrace emerging technologies for optimal data standardization in the dynamic field of Alzheimer's disease research.

5.1.2 Algorithmic Standards:

The quest to advance Alzheimer's disease detection is propelled by Neuro Quest's implementation of high algorithmic standards. Through robust and interpretable models, and ethical data usage,Neuro Quest prioritizes transparency, reproducibility, and collaboration within the scientific community. The commitment to standardized evaluation metrics, rigorous testing, and continuous refinement against benchmark datasets ensures the establishment of exemplary algorithmic standards. The dedication to regular updates and compliance with evolving standards underscores the pursuit of excellence in Alzheimer's detection through deep learning methodologies as CNN and Inceptionv3.

5.2 Impacts

5.2.1 Early Detection, classification and Intervention:

This application of deep learning algorithms as CNN and InceptionV3 enables early detection of subtle cognitive changes, empowering proactive interventions by healthcare professionals. This not only improves individual outcomes but also alleviates the societal and economic burden on healthcare systems. The initiative's contribution to research is noteworthy, opening avenues for innovative therapeutics and advancing our understanding of Alzheimer's. In essence, Neuro Quest's pioneering work promises a future where early intervention becomes a reality, shaping the landscape of Alzheimer's care and offering hope in the ongoing battle against this debilitating disease.

5.2.2 Research Acceleration:

The application of deep learning algorithms as CNN and InceptionV3 in Alzheimer's disease detection, as explored in "Neuro Quest: Advancing Alzheimer's Disease Detection using Deep Learning Algorithms," has ushered in a new era of research acceleration with profound impacts. These sophisticated algorithms leverage complex neural networks to analyze vast datasets, enabling swift identification of patterns indicative of Alzheimer's disease. The speed and accuracy achieved through deep learning significantly expedite the research process, allowing for more efficient screening and diagnosis. Researchers can now sift through extensive data sets, pinpointing subtle markers of the disease that may have otherwise gone unnoticed. This acceleration not only enhances the pace of discovery but also opens avenues for early detection,classification and intervention, potentially transforming the landscape of Alzheimer's research and patient care. The integration of deep learning algorithms in Neuro Quest promises to be a game-changer, propelling us closer to a future where Alzheimer's disease can be detected and addressed with unprecedented efficiency.

5.3 Ethics

5.3.1 Privacy Concerns:

In the pursuit of advancing Alzheimer's disease detection through the innovative application of deep learning algorithms in Neuro Quest, ethical considerations surrounding privacy emerge as a paramount concern. As the utilization of sensitive medical data becomes integral to the algorithm's training and diagnostic processes, safeguarding individuals' privacy is of utmost importance. Neuro Quest must uphold stringent data anonymization protocols, ensuring that patient identities remain confidential throughout the algorithmic development and deployment phases. A commitment to ethical data handling practices not only aligns with the principles of patient autonomy but also fortifies public trust in the pursuit of pioneering solutions for Alzheimer's disease detection. Constant vigilance, regular privacy audits, and adherence to evolving ethical standards will be essential in navigating the ethical landscape associated with Neuro Quest's groundbreaking advancements.

5.3.2 Informed Consent and Transparency:

In the pursuit of advancing Alzheimer's disease detection through our innovative project, Neuro Quest, we hold paramount the principles of ethics, with a specific focus on informed consent and transparency. Recognizing the sensitive nature of health-related data, we are committed to ensuring that individuals participating in our study fully comprehend the objectives, risks, and potential benefits associated with their involvement. Transparency is at the core of our approach, as we believe in fostering trust and accountability. We are dedicated to openly sharing details about our deep learning algorithms, methodologies, and the overall research process. This commitment extends to the dissemination of results, ensuring that participants and the broader community are kept informed about the progress and outcomes of Neuro Quest. Through these ethical practices, we aim to uphold the rights and well-being of our participants, contributing to the responsible and socially beneficial advancement of Alzheimer's disease detection using cutting-edge deep learning algorithms.

5.4 Challenges

In our journey to Alzheimer disease classification , we discovered a fascinating landscape of opportunities and challenges. One initial hurdle stemmed from the lack of readily available MRI dataset of Alzheimer.

5.4.1 Data Imbalances :

In the pursuit of advancing Alzheimer's disease detection through Neuro Quest's innovative deep learning algorithms, one of the foremost challenges faced is the presence of data imbalances. The inherent nature of medical datasets often leads to an uneven distribution of samples across different demographic groups, potentially resulting in skewed model training. This imbalance poses a significant hurdle in developing a robust and generalizable algorithm, as the model may inadvertently prioritize the majority class, leading to suboptimal performance for underrepresented groups.Addressing these challenges requires a nuanced approach, involving careful curation of representative datasets and incorporating ethical considerations throughout the algorithm's development process. Neuro Quest recognizes the critical importance of overcoming data imbalances to ensure the equitable and effective deployment of its deep learning algorithms in advancing Alzheimer's disease detection.

5.4.2 Interpretable Models:

The inherent complexity of deep learning models, such as Convolutional Neural Networks CNN, and InceptionV3, poses a significant obstacle to interpretability. The intricate hierarchical structures of these models make it challenging to discern the specific features or patterns that contribute to Alzheimer's disease prediction. Secondly, the interpretability of these models is crucial for gaining the trust of healthcare professionals and ensuring the responsible deployment of AI in medical settings. However, achieving interpretability without sacrificing the high performance of deep learning models remains a delicate balance.Overcoming these challenges will be pivotal in advancing the adoption of deep learning algorithms for Alzheimer's disease detection, ensuring not only high accuracy but also transparency and interpretability in the decision-making process.

5.4.3 Overfitting and Underfitting:

While the model implemented underfitting and overfitting have occurred but mostly overfitting happens too much because of lack of dataset and model structure so that's why there are too many times fit the model, check result, and change the structure of models

Chapter - 06

6 Constraints and Alternatives

6.1 Data Limitations and Diversity Constraints

Data size and availability: Training deep learning models for Alzheimer's disease (AD) diagnosis often requires large, diverse datasets of medical images and clinical data. This limited data availability can lead to overfitting, where the model memorizes the training data but fails to generalize to unseen examples.

Data diversity biases: Existing AD datasets may not adequately represent the full spectrum of the disease, particularly underrepresented populations or diverse clinical presentations. Biases in data collection can lead to models that perform poorly on specific demographics, hindering their real-world applicability and ethical considerations.

6.2 Interpretability and Explainability Challenges

In the pursuit of advancing Alzheimer's disease detection through this application of deep learning algorithms, particularly Convolutional Neural Networks (CNN), InceptionV3, the challenge of interpretability and explainability emerges as a critical consideration. These sophisticated models, while achieving remarkable accuracy, often operate as complex black-box systems, making it challenging for clinicians and researchers to comprehend the underlying decision-making processes. The lack of interpretability poses constraints on the broader acceptance and clinical integration of these models. Addressing this challenge is imperative to ensure that the predictions and diagnostic insights generated by the models can be effectively communicated and validated within the medical community.

6.3 Ethical and Privacy Considerations

Sharing sensitive medical data for research necessitates robust anonymization and strong data security measures to protect individual privacy. Transparency in model explainability is crucial to building trust and understanding how decisions are made. Comprehensive consent procedures must be implemented, clearly explaining potential risks and benefits, and respecting the right to withdraw. Finally, considering the psychological impact of potential diagnoses, frameworks for psychosocial support and informed decision-making should be integrated into any deployment strategy.

Chapter - 07

7 Schedules, Tasks, and Milestones

Schedules, tasks, and milestones are crucial in managing Alzheimer's disease research projects. Schedules provide a timeline for activities, ensuring efficient use of resources. Tasks break down complex objectives into manageable steps, enhancing team coordination. Milestones serve as measurable markers, allowing progress assessment and ensuring project alignment with goals, ultimately optimizing the overall project management process.

7.1 Data Acquisition and Preprocessing (1 months)

During the initial phase of the Alzheimer's disease research project, the focus will be on Data Acquisition and Preprocessing, spanning one months. This period is dedicated to gathering relevant data sources and implementing preprocessing techniques to ensure the quality and readiness of data for subsequent analysis.

7.2 Deep Learning Model Development and Training (1.5 months)

In the pivotal phase of the Alzheimer's research project, we embark on a four-month journey dedicated to Deep Learning Model Development and Training. Leveraging cutting-edge techniques such as Convolutional Neural Networks (CNN) and the inception model, our aim is to craft a powerful model capable of deciphering intricate patterns within Alzheimer's data.

7.3 Model Evaluation, Interpretation, and Dissemination (1 months)

In the concluding phase of our Alzheimer's research project, spanning three months, we focus on Model Evaluation, Interpretation, and Dissemination. Rigorous evaluation protocols will be implemented to gauge the model's performance, followed by insightful interpretation of results.

Chapter - 08

8 Conclusion

8.1 Introduction

In conclusion, our exploration of MRI data in the context of Alzheimer's disease unfolds a multifaceted narrative. The journey through data acquisition, preprocessing, deep learning model development, and evaluation has illuminated intricate patterns within the neurological landscape. As we decipher the implications of our findings, this comprehensive report serves not only as a testament to our dedication but also as a catalyst for future advancements in understanding and addressing Alzheimer's disease through innovative MRI-based approaches.

8.2 Limitation

1. **Data Variability:** The study may encounter limitations due to the inherent variability in MRI data, influenced by factors such as image quality, patient demographics, and scanner variations.

2. **Model Generalization:** Despite robust training, the deep learning model's generalization to diverse populations and datasets may be a limitation, impacting its applicability beyond the current study context.

3. **Resource Constraints:** The availability of computational resources and time constraints during the model development and training phases may have implications for the depth and complexity of the implemented neural network architecture.

4. **Interpretability Challenges:** Complex deep learning models, including the inception model, may pose challenges in interpreting the decision-making processes, potentially limiting our ability to provide detailed insights into the features influencing predictions.

5. **Clinical Validation:** The study's findings, while promising, may require further validation in clinical settings to establish the real-world efficacy of the developed

model in diagnosing Alzheimer's disease.

6. **Ethical Considerations:** Ethical considerations related to data privacy, informed consent, and responsible use of AI in healthcare may introduce limitations that impact the scope and implementation of the study.

8.3 Future Works

We Developed deep-learning models for Alzheimer's disease detection but in the future, we will develop more:

- We will try to increase our dataset.As our dataset is not large we will increase our Alzheimer's MRI data.
- For increased dataset we will use the GAN deep learning model to generate images as real-time data.
- We will model a more complex model for Alzheimer's disease detection

References

[1] Abdulaziz Alorf and Muhammad Usman Ghani Khan. Multi-label classification of alzheimer's disease stages from resting-state fmri-based correlation connectivity data and deep learning. *Computers in Biology and Medicine*, 151:106240, 2022.

[2] Colin Birkenbihl, Yasamin Salimi, Daniel Domingo-Fernándéz, Simon Lovestone, AddNeuroMed Consortium, Holger Fröhlich, Martin Hofmann-Apitius, Japanese Alzheimer's Disease Neuroimaging Initiative, and Alzheimer's Disease Neuroimaging Initiative. Evaluating the alzheimer's disease data landscape. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, 6(1):e12102, 2020.

[3] Jacqueline Chyr, Haoran Gong, and Xiaobo Zhou. Dota: Deep learning optimal transport approach to advance drug repositioning for alzheimer's disease. *Biomolecules*, 12(2):196, 2022.

[4] Jack C de la Torre. Vascular risk factor detection and control may prevent alzheimer's disease. *Ageing research reviews*, 9(3):218–225, 2010.

[5] Vasco Sá Diogo, Hugo Alexandre Ferreira, Diana Prata, and Alzheimer's Disease Neuroimaging Initiative. Early diagnosis of alzheimer's disease using machine learning: a multi-diagnostic, generalizable approach. *Alzheimer's Research & Therapy*, 14(1):107, 2022.

[6] Wei Feng, Nicholas Van Halm-Lutterodt, Hao Tang, Andrew Mecum, Mohamed Kamal Mesregah, Yuan Ma, Haibin Li, Feng Zhang, Zhiyuan Wu, Erlin Yao, et al. Automated mri-based deep learning model for detection of alzheimer's disease process. *International Journal of Neural Systems*, 30(06):2050032, 2020.

[7] Guilherme Folego, Marina Weiler, Raphael F Casseb, Ramon Pires, and Anderson Rocha. Alzheimer's disease detection through whole-brain 3d-cnn mri. *Frontiers in bioengineering and biotechnology*, 8:534592, 2020.

[8] GB Frisoni, C Testa, A Zorzan, F Sabattoli, A Beltramello, H Soininen, and MP Laakso. Detection of grey matter loss in mild alzheimer's disease with voxel

based morphometry. *Journal of Neurology, Neurosurgery & Psychiatry*, 73(6):657–664, 2002.

[9] Taher M Ghazal, Sagheer Abbas, Sundus Munir, MA Khan, Munir Ahmad, Ghassan F Issa, Syeda Binish Zahra, Muhammad Adnan Khan, and Mohammad Kamrul Hasan. Alzheimer disease detection empowered with transfer learning. *Computers, Materials & Continua*, 70(3), 2022.

[10] Jyoti Islam and Yanqing Zhang. Brain mri analysis for alzheimer's disease diagnosis using an ensemble system of deep convolutional neural networks. *Brain informatics*, 5:1–14, 2018.

[11] Walaa N Ismail, Fathimathul Rajeena PP, and Mona AS Ali. A meta-heuristic multi-objective optimization method for alzheimer's disease detection based on multi-modal data. *Mathematics*, 11(4):957, 2023.

[12] Taeho Jo, Kwangsik Nho, and Andrew J Saykin. Deep learning in alzheimer's disease: diagnostic classification and prognostic prediction using neuroimaging data. *Frontiers in aging neuroscience*, 11:220, 2019.

[13] AS Khachaturian, A Dengel, V Dočkal, P Hroboň, and M Tolar. Accelerating innovations for enhanced brain health. can artificial intelligence advance new pathways for drug discovery for alzheimer's and other neurodegenerative disorders? *The Journal of Prevention of Alzheimer's Disease*, pages 1–4, 2023.

[14] Suhuai Luo, Xuechen Li, and Jiaming Li. Automatic alzheimer's disease recognition from mri data using deep learning method. *Journal of Applied Mathematics and Physics*, 5(9):1892–1898, 2017.

[15] Suriya Murugan, Chandran Venkatesan, MG Sumithra, Xiao-Zhi Gao, B Elakkiya, Muthuramalingam Akila, and S Manoharan. Demnet: a deep learning model for early diagnosis of alzheimer diseases and dementia from mr images. *IEEE Access*, 9:90319–90329, 2021.

[16] Amir Nazem and G Ali Mansoori. Nanotechnology for alzheimer's disease detection and treatment. *Insciences J.*, 1(4):169–193, 2011.

[17] Ryszard Pluta, Marzena Ułamek-Kozioł, Sławomir Januszewski, and Stanisław Czuczwar. Platelets, lymphocytes and erythrocytes from alzheimer's disease patients: the quest for blood cell-based biomarkers. *Folia Neuropathologica*, 56(1):14–20, 2018.

[18] F M Javed Mehedi Shamrat, Shamima Akter, Sami Azam, Asif Karim, Pronab Ghosh, Zarrin Tasnim, Khan Md. Hasib, Friso De Boer, and Kawsar Ahmed. Alzheimernet: An effective deep learning based proposition for alzheimer's disease stages classification from functional brain changes in magnetic resonance images. *IEEE Access*, 11:16376–16395, 2023.

[19] Rachel Swainson, JR Hodges, CJ Galton, J Semple, A Michael, BD Dunn, JL Iddon, TW Robbins, and BJ Sahakian. Early detection and differential diagnosis of alzheimer's disease and depression with neuropsychological tasks. *Dementia and geriatric cognitive disorders*, 12(4):265–280, 2001.

[20] Michael W Weiner, Dallas P Veitch, Paul S Aisen, Laurel A Beckett, Nigel J Cairns, Jesse Cedarbaum, Robert C Green, Danielle Harvey, Clifford R Jack, William Jagust, et al. 2014 update of the alzheimer's disease neuroimaging initiative: a review of papers published since its inception. *Alzheimer's & dementia*, 11(6):e1–e120, 2015.

[21] Yudong Zhang, Zhengchao Dong, Preetha Phillips, Shuihua Wang, Genlin Ji, Jiquan Yang, and Ti-Fei Yuan. Detection of subjects and brain regions related to alzheimer's disease using 3d mri scans based on eigenbrain and machine learning. *Frontiers in computational neuroscience*, 9:66, 2015.

[22] Jiayi Zhu, Ying Tan, Rude Lin, Jiaqing Miao, Xuwei Fan, Yafei Zhu, Ping Liang, Jinnan Gong, and Hui He. Efficient self-attention mechanism and structural distilling model for alzheimer's disease diagnosis. *Computers in Biology and Medicine*, 147:105737, 2022.